WO2011071883A1 - Anti-inflammatory antibodies and uses therefor - Google Patents
Anti-inflammatory antibodies and uses therefor Download PDFInfo
- Publication number
- WO2011071883A1 WO2011071883A1 PCT/US2010/059234 US2010059234W WO2011071883A1 WO 2011071883 A1 WO2011071883 A1 WO 2011071883A1 US 2010059234 W US2010059234 W US 2010059234W WO 2011071883 A1 WO2011071883 A1 WO 2011071883A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- group
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 40
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 155
- 150000007523 nucleic acids Chemical class 0.000 claims description 106
- 102000039446 nucleic acids Human genes 0.000 claims description 89
- 108020004707 nucleic acids Proteins 0.000 claims description 89
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 72
- 239000002773 nucleotide Substances 0.000 claims description 54
- 125000003729 nucleotide group Chemical group 0.000 claims description 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 45
- 241000282414 Homo sapiens Species 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 28
- 210000004408 hybridoma Anatomy 0.000 claims description 25
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 24
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 21
- 206010063837 Reperfusion injury Diseases 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 13
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 12
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 7
- 208000028867 ischemia Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 abstract description 27
- 230000004913 activation Effects 0.000 abstract description 13
- 241000699670 Mus sp. Species 0.000 description 55
- 239000000427 antigen Substances 0.000 description 53
- 108091007433 antigens Proteins 0.000 description 48
- 102000036639 antigens Human genes 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 41
- 230000027455 binding Effects 0.000 description 39
- 150000001413 amino acids Chemical class 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 36
- 230000006378 damage Effects 0.000 description 32
- 208000027418 Wounds and injury Diseases 0.000 description 30
- 208000014674 injury Diseases 0.000 description 30
- 108060003951 Immunoglobulin Proteins 0.000 description 25
- 102000018358 immunoglobulin Human genes 0.000 description 25
- 230000001717 pathogenic effect Effects 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 25
- 210000003719 b-lymphocyte Anatomy 0.000 description 24
- 230000002950 deficient Effects 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 230000037361 pathway Effects 0.000 description 15
- 230000010410 reperfusion Effects 0.000 description 15
- 241001529936 Murinae Species 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 230000004927 fusion Effects 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- 108091008875 B cell receptors Proteins 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 102100032768 Complement receptor type 2 Human genes 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- -1 IgM Chemical compound 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000000415 inactivating effect Effects 0.000 description 6
- 208000037906 ischaemic injury Diseases 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 102000006834 complement receptors Human genes 0.000 description 5
- 108010047295 complement receptors Proteins 0.000 description 5
- 230000004154 complement system Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 101710143772 Complement receptor type 2 Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 4
- 208000019693 Lung disease Diseases 0.000 description 4
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 4
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 102000013394 Troponin I Human genes 0.000 description 4
- 108010065729 Troponin I Proteins 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100022133 Complement C3 Human genes 0.000 description 3
- 102100030886 Complement receptor type 1 Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 3
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000285 follicular dendritic cell Anatomy 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010028780 Complement C3 Proteins 0.000 description 2
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 2
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 206010022941 Iridocyclitis Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000054751 human RUNX1T1 Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010028778 Complement C4 Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101150052726 DSP2 gene Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101000583007 Dictyostelium discoideum Myosin-2 heavy chain Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- MDCTVRUPVLZSPG-BQBZGAKWSA-N His-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 MDCTVRUPVLZSPG-BQBZGAKWSA-N 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100021797 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Human genes 0.000 description 1
- 101710174326 Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002729 catgut Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 102000056549 human Fv Human genes 0.000 description 1
- 108700005872 human Fv Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 108010023260 immunoglobulin Fv Proteins 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000037817 intestinal injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
Definitions
- Acute inflammatory responses can result from a wide range of diseases and naturally occurring events such as stroke and myocardial infarction. Common medical procedures can also lead to localized and systemic inflammation. Left untreated
- inflammation can result in significant tissue loss and may ultimately lead to multi-system failure and death. Interfering with the inflammatory response after injury may be one method to reduce tissue loss. Accumulating evidence supports a major role for the serum innate response or complement system in inflammation.
- Inflammatory diseases or disorders are potentially life -threatening, costly, and affect a large number of people every year. Thus, effective treatments of inflammatory diseases or disorders are needed.
- the invention features isolated antibodies, in particular IgGs, that bind to the N2 self-peptide and inhibit inflammation.
- the antibodies are capable of inhibiting activation of complement, thereby inhibiting an immune response to the N2 self-peptide.
- the antibody has a light chain variable region comprising the amino acid sequence shown as SEQ ID NO: 8 or 20.
- the antibody has a heavy chain variable region comprising the amino acid sequence shown as SEQ ID NO: 2 or 14.
- the antibody is produced by ATCC Accession Number PTA-9392.
- the antibody is produced by ATCC Accession Number PTA-9393.
- the invention features nucleic acids encoding the antiinflammatory antibodies, as well as vectors and host cells expressing the same.
- the invention features methods of inhibiting activation of an immune response to the N2 self-peptide in a subject by administering to the subject an antiinflammatory antibody described herein.
- the invention features methods of treating an inflammatory disease, such as e.g., ischemia-reperfusion injury, in a subject by administering to the subject a pharmaceutical composition comprising an isolated antiinflammatory antibody as described herein.
- Figure 1 shows antibody heavy and light chain sequences of murine B-cell hybridoma 12A6 (PTA-9392).
- A shows the IgG 12A6 (or 12A6 IgG) heavy chain nucleic acid sequence (SEQ ID NO: 1) and the amino acid sequence corresponding to the heavy chain sequence of SEQ ID NO: 1 (SEQ ID NO: 2).
- Framework regions (FVWR) and complementarity-determining regions (CDR) are indicated above the nucleotides.
- Figure 1A discloses the CDRl, CDR2 and CDR 3 domain nucleotide and encoded amino acid sequences as SEQ ID NOS 3-6 and 25-26 respectively, in order of appearance.
- FIG. 1 shows the IgG 12A6 (or 12A6 IgG) light chain nucleic acid sequence (SEQ ID NO: 7) and the amino acid sequence corresponding to the light chain sequence of SEQ ID NO: 7 (SEQ ID NO: 8).
- Framework regions (FVWR) and complementarity-determining regions (CDR) are indicated above the nucleotides.
- Figure IB discloses the CDRl, CDR2 and CDR3 domain nucleotide and encoded amino acid sequences as SEQ ID NOS 9-12 and 27-28 respectively, in order of appearance.
- Figure 2 shows antibody heavy and light chain sequences of murine B-cell hybridoma 21G6 (PTA-9393).
- A shows the IgG 21G6 (or 21G6 IgG) heavy chain nucleic acid sequence (SEQ ID NO: 13) and the amino acid sequence corresponding to the heavy chain sequence of SEQ ID NO: 13 (SEQ ID NO: 14).
- Framework regions (FVWR) and complementarity-determining regions (CDR) are indicated above the nucleotides.
- Figure 2A discloses the CDR1, CDR2 and CDR3 domain nucleotide and encoded amino acid sequences as SEQ ID NOS 15-18 and 29-30 respectively, in order of appearance.
- FIG. 19 shows the IgG 21G6 (or 21G6 IgG) light chain nucleic acid sequence (SEQ ID NO: 19) and the amino acid sequence corresponding to the light chain sequence of SEQ ID NO: 19 (SEQ ID NO: 20).
- Framework regions (FVWR) and complementarity-determining regions (CDR) are indicated above the nucleotides.
- Figure 2B discloses the CDR1, CDR2 and CDR3 domain nucleotide and encoded amino acid sequences as SEQ ID NOS 21-24 and 31-32 respectively, in order of appearance.
- Figure 3 shows that murine anti-N2 mAb (anti-N2 F(ab ' ) 2 antibody (21G6)) inhibits inflammation following myocardial infarction.
- Figure 4 shows that N2 peptide and anti-N2 mAb (anti-N2 F(ab ' ) 2 antibody (21G6)) block human IgM -mediated injury.
- Figure 5 shows binding of the 12A6 hybridoma antibody to antigen released in small vessels in the heart after reperfusion
- Figure 6 shows the results of a blocking experiment with an Fab'2 fragment of 12A6 as compared to 21G6.
- a and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article.
- an element means one element or more than one element.
- Amino acid is used herein to refer to either natural or synthetic amino acids, including glycine and D or L optical isomers, and amino acid analogs and peptidomimetics.
- Antibody is used herein to refer to binding molecules including immunoglobulin molecules, antibody fragments, and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen-binding site.
- Immunoglobulin molecules useful in the invention can be of any class (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass. Native antibodies and immunoglobulins are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains.
- Each heavy chain has at one end a variable domain followed by a number of constant domains.
- Each light chain has a variable domain at one end and a constant domain at its other end.
- Antibodies include, but are not limited to, polyclonal, monoclonal, bispecific, chimeric, partially or fully humanized antibodies, fully human antibodies (i.e., generated in a transgenic mouse expressing human immunoglobulin genes), camel antibodies, and anti- idiotypic antibodies.
- An antibody, or generally any molecule "binds specifically" to an antigen (or other molecule) if the antibody binds preferentially to the antigen, and, e.g., has less than about 30%, preferably 20%, 10%>, or 1% cross-reactivity with another molecule.
- the terms "antibody” and "immunoglobulin” are used interchangeably.
- Antibody fragment is used herein to refer to any derivative of an antibody which is less than full-length. In exemplary embodiments, the antibody fragment retains at least a significant portion of the full-length antibody's specific binding ability. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab') 2 , scFv, Fv, dsFv diabody, minibody, Fc, Fd fragments, and single chain antibodies.
- the antibody fragment may be produced by any means. For instance, the antibody fragment may be enzymatically or chemically produced by fragmentation of an intact antibody, it may be recombinantly produced from a gene encoding the partial antibody sequence, or it may be wholly or partially synthetically produced.
- the antibody fragment may optionally be a single chain antibody fragment. Alternatively, the fragment may comprise multiple chains which are linked together, for instance, by disulfide linkages. The fragment may also optionally be a multimolecular complex.
- a functional antibody fragment will typically comprise at least about 50 amino acids and more typically will comprise at least about 200 amino acids.
- Antigen-binding site is used herein to refer to the variable domain of a heavy chain associated with the variable domain of a light chain.
- Cells or “host cells” are terms used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
- a "consensus” sequence refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See. e.g.,
- each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence.
- a "consensus framework” refers to the framework region in the consensus immunoglobulin sequence.
- a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain.
- Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
- a predicted nonessential amino acid residue in an immunoglobulin can be preferably replaced with another amino acid residue from the same side chain family.
- mutations can be introduced randomly along all or part of an immunoglobulin coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity.
- Interaction refers to a physical association between two or more molecules, e.g., binding.
- the interaction may be direct or indirect.
- Inflammatory disease is used herein to refer to a disease or disorder that is caused or contributed to by a complicated set of functional and cellular adjustments involving acute or chronic changes in microcirculation, movement of fluids, and influx and activation of inflammatory cells (e.g., leukocytes) and complement, and included autoimmune diseases.
- inflammatory cells e.g., leukocytes
- complement e.g., IL-4, IL-12
- CNS Central Nervous System
- gastrointestinal system the skin and associated structures, the immune system, the hepato-biliary system, or any site in the body where pathology can occur with an inflammatory component.
- an "isolated” molecule e.g., an isolated antibody, refers to a condition of being separate or purified from other molecules present in the natural environment.
- Natural IgM is used herein to refer to an IgM antibody that is naturally produced in a mammal (e.g., a human). They have a pentameric ring structure wherein the individual monomers resemble IgGs thereby having two light ( ⁇ or ⁇ ) chains and two heavy ( ⁇ ) chains. Further, the heavy chains contain an additional C H domain. The monomers form a pentamer by disulfide bonds between adjacent heavy chains. The pentameric ring is closed by the disulfide bonding between a J chain and two heavy chains. Because of its high number of antigen binding sites, an IgG antibody is an effective agglutinator of antigen.
- IgM is the first immunoglobulin synthesized in an antibody response. IgMs are described in U.S. Pat. No. 7,442,783, the entire contents of which are specifically incorporated herein by reference.
- Nucleic acid is used herein to refer to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA).
- RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.
- coding sequence is "operably linked" to another coding sequence when RNA polymerase will transcribe the two coding sequences into a single mRNA, which is then translated into a single polypeptide having amino acids derived from both coding sequences.
- the coding sequences need not be contiguous to one another so long as the expressed sequences ultimately process to produce the desired protein.
- An expression control sequence operatively linked to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the expression control sequences.
- expression control sequences refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence.
- expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (i.e., ATG) in front of a protein-encoding gene, splicing signals for introns, maintenance of the correct reading frame of that gene to permit proper translation of the mRNA, and stop codons.
- control sequences is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. Expression control sequences can include a promoter.
- Peptide is used herein to refer to a polymer of amino acids of relatively short length (e.g. less than 50 amino acids).
- the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
- the term also encompasses an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.
- Promoter is used herein to refer to a minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific, tissue-specific, or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the of a polynucleotide sequence. Both constitutive and inducible promoters, are included in the invention (see e.g., Bitter et al, Methods in Enzymology 153:516-544, 1987).
- inducible promoters such as pL of bacteriophage, plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used.
- promoters derived from the genome of mammalian cells e.g., metallothionein promoter
- mammalian viruses e.g., the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter
- Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of the invention.
- Tissue-specific regulatory elements may be used. Including, for example, regulatory elements from genes or viruses that are differentially expressed in different tissues.
- Specifically binds or “immunospecifically binds” is used herein to refer to the interaction between two molecules to form a complex that is relatively stable under physiologic conditions.
- the term is used herein in reference to various molecules, including, for example, the interaction of an antibody and an antigen (e.g. a peptide).
- Specific binding can be characterized by a dissociation constant of at least about lxlO 6 M, generally at least about lxl 0 "7 M, usually at least about lxl 0 "8 M, and particularly at least about lxl 0 "9 M or lxl 0 ⁇ 10 M or greater.
- Methods for determining whether two molecules specifically bind are well known and include, for example, equilibrium dialysis, surface plasmon resonance, and the like.
- “Stringency hybridization” or “hybridizes under low stringency, medium stringency, high stringency, or very high stringency conditions” is used herein to describes conditions for hybridization and washing.
- Guidance for performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1- 6:3.6, which is incorporated by reference. Aqueous and non-aqueous methods are described in that reference and either can be used.
- hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by two washes in 0.2X SSC, 0.1% SDS at least at 50°C (the temperature of the washes can be increased to 55°C for low stringency conditions); 2) medium stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C; 3) high stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1%) SDS at 65°C; and preferably 4) very high stringency hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1%) SDS at 65°C. Very high stringency conditions (4) are the preferred conditions and the ones that should be used unless otherwise specified. Calculations of homology or
- the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
- the length of a reference sequence aligned for comparison purposes is at least 30%>, preferably at least 40%>, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence.
- the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
- the percent identity between the two sequences is a function of the number of identical positions shared by the sequences and the percent homology between two sequences is a function of the number of conserved positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
- the comparison of sequences and determination of percent identity and/or homology between two sequences can be accomplished using a mathematical algorithm.
- the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol.
- the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available on the world wide web with the extension gcg.com), using a NWSgapdna CMP matrix and a gap weight of 40, 50, 60, 70; or 80 and a length weight of 1 , 2, 3, 4, 5, or 6.
- a particularly preferred set of parameters are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frame shift gap penalty of 5.
- the percent identity and/or homology between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- Treating is used herein to refer to any treatment of, or prevention of, or inhibition of a disorder or disease in a subject and includes by way of example: (a) preventing the disease or disorder from occurring in a subject that may be predisposed to the disease or disorder, but has not yet been diagnosed as having it; (b) inhibiting the disease or disorder, i.e., arresting its progression; or (c) relieving or ameliorating the disease or disorder, i.e., causing regression.
- treating as used herein includes, for example, repair and regeneration of damaged or injured tissue or cells at the site of injury or prophylactic treatments to prevent damage, e.g., before surgery.
- Vector refers to a nucleic acid molecule, which is capable of transporting another nucleic acid to which it has been operatively linked and can include a plasmid, cosmid, or viral vector.
- a plasmid i.e., a nucleic acid capable of extra-chromosomal replication.
- Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked.
- Vectors may be capable of directing the expression of genes to which they are operatively linked.
- a vector may also be capable of integrating into the host DNA.
- plasmid and vector are used interchangeably as a plasmid (a circular arrangement of double stranded DNA) is the most commonly used form of a vector.
- Viral vectors include, e.g., replication defective retroviruses, adenoviruses and adeno- associated viruses.
- the present invention is based, at least in part, on the identification of antibodies that bind to the N2 self peptide and inhibit inflammation.
- Certain antibodies may be obtained from a hybridoma that has been deposited with the American Type Culture Collection and provided Accession Number PTA-9392 (IgG 12A6 ) or PTA-9393 (IgG 21G6 ).
- the present invention provides an isolated antibody that specifically binds to an amino acid sequence comprising the N2 self-peptide of Mouse NMHC-IIB (592-603) (LMKNMDPLNDNV (N2; SEQ ID NO:33)).
- the antiinflammatory antibody specifically binds to an amino acid sequence encoded by a nucleic acid comprising YTN ATG AAR AAY ATG GAY CCN YTN AAY GAY AAY GTN (SEQ ID NO: 34), where an "R” corresponds to a base that may be a A or G; a "Y” corresponds to a base that may be a C or T; and an "N” corresponds to a base that may be an A, C, G or T, and is capable of inhibiting inflammation in a subject to whom the antibody is administered.
- N2 is a self-antigen and in particular an ischemic antigen, or an antigen expressed or exposed on damaged ischemic tissue.
- Natural IgM recognizes and binds N2 expressed or exposed on damaged tissue, and in particular damaged ischemic tissue, and thereby initiates inflammation by activating complement in the classical pathway.
- the anti-inflammatory antibodies described herein compete with natural IgM antibodies in binding self-antigen, thereby titrating out self-antigen available to bind IgM and activate complement. When administered to a subject, the anti-inflammatory antibodies described herein inhibit activation of complement, thereby inhibiting inflammation.
- the present invention encompasses antibodies that immunospecifically bind to the N2 self-peptide having heavy chain variable region ("VH”) comprising one or more of the VH complementarity determining regions ("CDRs") shown in Figures 1 and 2.
- the present invention also encompasses antibodies that immunospecifically bind to the N2 self-peptide having a light chain variable region (“VL”) comprising one or more of the VL
- IgG 12A6 ( ⁇ 2 ⁇ 6 IgG)
- the nucleotide sequence of the heavy chain variable region of the IgG produced from hybridoma PTA-9392, IgG 12A6 (also referred to as 12A6 IgG) is shown in Figure 1A (SEQ ID NO: 1), and the amino acid sequence is also shown in Figure 1 A (SEQ ID NO: 2).
- the CDRl domain of the heavy chain variable region corresponds to a region of SEQ ID NO: 2 (shown as SEQ ID NO: 4), which is encoded by a region of SEQ ID NO: 1 (shown as SEQ ID NO: 3), and the CDR2 domain of the heavy chain variable region corresponds to a region of SEQ ID NO: 2 (shown as SEQ ID NO: 6), which is encoded by a region of SEQ ID NO: 1 (shown as SEQ ID NO: 5).
- the CDR3 domain of the heavy chain variable region corresponds to a region of SEQ ID NO: 2 (shown as SEQ ID NO: 26), which is encoded by a region of SEQ ID NO: 1 (shown as SEQ ID NO: 25) in Figure 1A.
- the nucleotide sequence of the light chain variable region of IgG 12A6 is shown in Figure IB (SEQ ID NO: 7), and the amino acid sequence is also shown in Figure IB (SEQ ID NO: 8).
- the CDRl domain of the light chain variable region corresponds to a region of SEQ ID NO: 8 (shown as SEQ ID NO: 10), which is encoded by a region of SEQ ID NO: 7 (shown as SEQ ID NO: 9), and the CDR2 domain of the light chain variable region corresponds to a region of SEQ ID NO: 8 (shown as SEQ ID NO: 12), which is encoded by a region of SEQ ID NO: 7 (shown as SEQ ID NO: 11) in Figure IB.
- the CDR3 domain of the light chain variable region corresponds to a region of SEQ ID NO: 8 (shown as SEQ ID NO: 28), which is encoded by a region of SEQ ID NO: 7 (shown as SEQ ID NO: 27) in Figure IB.
- nucleotide sequences can encode the amino acid sequences listed herein.
- nucleic acid compositions of the present invention while often in a native sequence (except for modified restriction sites and the like), from either cDNA, genomic or mixtures may be mutated, in accordance with standard techniques. For coding sequences, these mutations, may affect the amino acid sequence as desired.
- nucleotide sequences substantially identical to or derived from native V, D, J, constant, switches and other such sequences described herein are contemplated.
- an isolated nucleic acid can comprise an IgG 12A6 (or 12A6 IgG) heavy chain variable region nucleotide sequence having a nucleotide sequence as shown in Figure 1A (SEQ ID NO: 1), or a sequence, which is at least 80%, 90%, 95%, 96%, 97%), 98%o, or 99% identical to SEQ ID NO: 1.
- a nucleic acid molecule may comprise the heavy chain CDR1 nucleotide sequence of SEQ ID NO: 3, or a portion thereof. Further, the nucleic acid molecule may comprise the heavy chain CDR2 nucleotide sequence of SEQ ID NO: 5, or a portion thereof.
- the nucleic acid molecule may comprise the heavy chain CDR3 nucleotide sequence of SEQ ID NO: 25, or a portion thereof.
- the nucleic acid molecule comprises a heavy chain CDR1 nucleotide sequence of SEQ ID NO: 3, or portion thereof, and a heavy chain CDR2 nucleotide sequence of SEQ ID NO: 5, or portion thereof, and a heavy chain CDR3 nucleotide sequence of SEQ ID NO: 25, or portion thereof.
- the nucleic acid molecules of the present invention may comprise heavy chain sequences, e.g.
- nucleic acid molecules of the present invention may comprise heavy chain sequences, which hybridize under stringent conditions, e.g. low, medium, high or very high stringency conditions, to SEQ ID NOs: 1, 3, 5, or 25.
- the invention features nucleic acid molecules having at least 80%, 90%, 95%, 96%, 97 %, 98%, and 99% sequence identity with a nucleic acid molecule encoding a heavy chain polypeptide, e.g., a heavy chain polypeptide of SEQ ID NOs: 2, 4 ,6, or 26.
- the invention also features nucleic acid molecules which hybridize to nucleic acid sequences encoding a heavy chain variable region of an antibody or portion thereof, e.g., a heavy chain variable region of SEQ ID NO: 2, 4 ,6, or 26.
- the isolated nucleic acid encodes an IgG 12A6 (12A6 IgG) light chain variable region nucleotide sequence having a nucleotide sequence as shown in Figure IB (SEQ ID NO: 7), or a sequence at least 80%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 7.
- the nucleic acid molecule may comprise the light chain CDR1 nucleotide sequence of SEQ ID NO: 9, or a portion thereof.
- the nucleic acid molecule may comprise the light chain CDR2 nucleotide sequence of SEQ ID NO: 11, or a portion thereof.
- the nucleic acid molecule may comprise the light chain CDR3 nucleotide sequence of SEQ ID NO: 27, or a portion thereof.
- the nucleic acid molecule comprises a light chain CDR1 nucleotide sequence of SEQ ID NO: 9, or portion thereof, and a light chain CDR2 nucleotide sequence of SEQ ID NO: 11, or portion thereof, and a light chain CDR3 nucleotide sequence of SEQ ID NO: 27, or portion thereof.
- the nucleic acid molecules of the present invention may comprise light chain sequences, e.g.
- SEQ ID NOs: 7, 9, 11, 27, or combinations thereof or encompass nucleotides having at least 80%, 90%>, 95%, 96%, 97 %, 98%, and 99% sequence identity to SEQ ID NOs: 7, 9, 11, or 27.
- Further nucleic acid molecules may comprise light chain sequences, which hybridize under stringent conditions, e.g. low, medium, high or very high stringency conditions, to SEQ ID NOs: 7, 9 ,11, or 27.
- Nucleic acid molecules can have at least 80%, 90%, 95%, 96%, 97 %, 98% or 99% sequence identity with a nucleic acid molecule encoding a light chain polypeptide, e.g., a light chain polypeptide of SEQ ID NOs: 8, 10, 12, or 28.
- the invention also features nucleic acid molecules which hybridize to a nucleic acid sequence encoding a light chain variable region of an antibody or portion thereof, e.g., a light chain variable region of SEQ ID NOs: 8, 10, 12, or 28.
- the invention provides an isolated nucleic acid encoding a heavy chain CDR1 domain comprising the amino acid sequence of SEQ ID NO: 4, or a fragment or modified form thereof.
- This nucleic acid can encode only the CDR1 region or can encode an entire antibody heavy chain variable region or a fragment thereof.
- the nucleic acid can encode a heavy chain variable region having a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6.
- the invention provides an isolated nucleic acid encoding a heavy chain CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, or a fragment or modified form thereof.
- This nucleic acid can encode only the CDR2 region or can encode an entire antibody heavy chain variable region or a fragment thereof.
- the nucleic acid can encode a light chain variable region having a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 4.
- the invention provides an isolated nucleic acid encoding a light chain CDR1 domain comprising the amino acid sequence of SEQ ID NO: 10, or a fragment or modified form thereof.
- This nucleic acid can encode only the CDR1 region or can encode an entire antibody light chain variable region.
- the nucleic acid can encode a light chain variable region having a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 12.
- the isolated nucleic acid can also encode a light chain CDR2 domain comprising the amino acid sequence of SEQ ID NO: 12, or a fragment or modified form thereof.
- This nucleic acid can encode only the CDR2 region or can encode an entire antibody light chain variable region.
- the nucleic acid can encode a light chain variable region having a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 10.
- the nucleic acid encoding the heavy or light chain variable region can be of murine or human origin, or can comprise a combination of murine and human amino acid sequences.
- the nucleic acid can encode a heavy chain variable region comprising the CDR1 of SEQ ID NO: 2 (SEQ ID NO: 4) and/or the CDR2 of SEQ ID NO: 2 (SEQ ID NO: 6), and/or the CDR3 of SEQ ID NO: 2 (SEQ ID NO: 26) and a human framework sequence.
- the nucleic acid can encode a light chain variable region comprising the CDR1 of SEQ ID NO: 8 (SEQ ID NO: 10) and/or the CDR2 of SEQ ID NO: 8 (SEQ ID NO: 12), and/or the CDR3 of SEQ ID NO: 2 (SEQ ID NO: 26) and a human framework sequence.
- the invention further encompasses vectors containing the above-described nucleic acids and host cells containing the expression vectors.
- the invention also features polypeptides and fragments of the IgG 12A6 heavy chain variable regions and/or light chain variable regions. Any of the polypeptides encoded by nucleic acids described herein are within the scope of the invention.
- the isolated polypeptides comprise, for example, the amino acid sequences of SEQ ID NOs: 8, 10, 12, 28, or fragments or combinations thereof; or SEQ ID NO: 2, 4, 6, 26, or fragments or combinations thereof.
- the polypeptides of the present invention include polypeptides having at least, but not more than 20, 10, 5, 4, 3, 2, or 1 amino acid that differs from SEQ ID NOs: 8, 10, 12, 28, 2, 4, 6, or 26.
- polypeptides are polypeptides that retain biological activity, e.g., the ability to bind the N2 self-peptide, and/or the ability to inhibit activation of complement.
- the polypeptides comprise polypeptides having at least 80%, 90%>, 95%, 96%, 97%, 98%>, and 99% sequence identity with a light chain variable region, or portion thereof, e.g. a light chain variable region polypeptide of SEQ ID NOs: 8, 10, 12, or 28.
- the polypeptides comprise polypeptides having at least 80%, 90%, 95%, 96%), 97%), 98%o, and 99% sequence identity with a heavy chain variable region, or portion thereof, e.g. a heavy chain variable region polypeptide of SEQ ID NOs: 2, 4, 6, or 26.
- the invention features a polypeptide comprising the amino acid sequence of SEQ ID NO: 8 and SEQ ID NO: 2, further comprising an IRES sequence.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDRl having the amino acid sequence of SEQ ID NO:4. In another embodiment, antibodies that immunospecifically bind to the N2 self- peptide comprise a VH CDR2 having the amino acid sequence of SEQ ID NO:6. In another embodiment, antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDR3 having the amino acid sequence of SEQ ID NO:26.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDRl having the amino acid sequence of SEQ ID NO:4 and a VH CDR2 having the amino acid sequence of SEQ ID NO:6.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDRl having the amino acid sequence of SEQ ID NO:4 and a VH CDR3 having the amino acid of SEQ ID NO:26.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDR2 having the amino acid sequence of SEQ ID NO: 6 and a VH CDR3 having the amino acid of SEQ ID NO:26.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDRl having the amino acid sequence of SEQ ID NO:4, a VH CDR2 having the amino acid sequence of SEQ ID NO:6, and a VH CDR3 having the amino acid of SEQ ID NO:26.
- antibodies that immunospecifically bind to an N2 self-peptide comprise a VL CDRl having the amino acid sequence of SEQ ID NO: 10. In another embodiment, antibodies that immunospecifically bind to the N2 self- peptide comprise a VL CDR2 having the amino acid sequence of SEQ ID NO: 12. In another embodiment, antibodies that immunospecifically bind to the N2 self-peptide comprise a VL CDR3 having the amino acid sequence of SEQ ID NO:28.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VL CDRl having the amino acid sequence of SEQ ID NO: 10 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 12.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VL CDRl having the amino acid sequence of SEQ ID NO: 10 and a VL CDR3 having the amino acid of SEQ ID NO:28.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VL CDR2 having the amino acid sequence of SEQ ID NO: 12 and a VL CDR3 having the amino acid of SEQ ID NO:28.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VL CDRl having the amino acid sequence of SEQ ID NO: 10, a VL CDR2 having the amino acid sequence of SEQ ID NO: 12, and a VL CDR3 having the amino acid of SEQ ID NO:28.
- the present invention also provides antibodies comprising one or more VH CDRs and one or more VL CDRs as shown in Figures 1 and 2.
- the invention provides for an antibody comprising a VH CDRl and a VL CDRl, a VH CDRl and a VL CDR2, a VH CDRl and a VL CDR3, a VH CDR2 and a VL CDRl, VH CDR2 and VL CDR2, a VH CDR2 and a VL CDR3, a VH CDR3 and a VH CDRl, a VH CDR3 and a VL CDR2, a VH CDR3 and a VL CDR3, or any combination thereof of the VH CDRs and VL CDRs shown in Figures 1 and 2.
- an antibody of the invention comprises a VH CDRl having the amino acid sequence of SEQ ID NO:4 and a VL CDRl having the amino acid sequence of SEQ ID NO: 10.
- an antibody of the present invention comprises a VH CDRl having the amino acid sequence of SEQ ID NO:4 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 12.
- an antibody of the present invention comprises a VH CDRl having the amino acid sequence of SEQ ID NO:4 and a VL CDR3 having the amino acid sequence of SEQ ID NO:28.
- an antibody of the present invention comprises a VH CDR2 having the amino acid sequence of SEQ ID NO: 6 and a VL CDRl having the amino acid sequence of SEQ ID NO: 10. In another embodiment, an antibody of the present invention comprises a VH CDR2 having the amino acid sequence of SEQ ID NO: 6 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 12. In another embodiment, an antibody of the present invention comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:6 and a VL CDR3 having the amino acid sequence of SEQ ID NO:28.
- an antibody of the present invention comprises a VH CDR3 having the amino acid sequence of SEQ ID NO: 14, and a VL CDRl having the amino acid sequence of SEQ ID NO: 10.
- an antibody of the present invention comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:26 and a VL CDR2 having the amino acid sequence of SEQ ID NO: 12.
- an antibody of the present invention comprises a VH CDR3 having the amino acid sequence of SEQ ID NO: 14 and a VL CDR3 having the amino acid sequence of SEQ ID NO:28.
- the nucleotide sequence of the heavy chain variable region of the IgG produced from hybridoma PTA-9393, IgG 21G6 (also referred to as 21G6 IgG) is shown in Figure 2A (SEQ ID NO: 13), and the amino acid sequence is also shown in Figure 2 A (SEQ ID NO: 14).
- the CDR1 domain of the heavy chain variable region corresponds to a region of SEQ ID NO: 14 (shown as SEQ ID NO: 16), which is encoded by a region of SEQ ID NO: 13 (shown as SEQ ID NO: 15), and the CDR2 domain of the heavy chain variable region corresponds to a region of SEQ ID NO: 14 (shown as SEQ ID NO: 18), which is encoded by a region of SEQ ID NO: 13 (shown as SEQ ID NO: 17).
- the CDR3 domain of the heavy chain variable region corresponds to a region of SEQ ID NO: 14 (shown as SEQ ID NO: 30), which is encoded by a region of SEQ ID NO: 13 (shown as SEQ ID NO: 29).
- the nucleotide sequence of the light chain variable region of IgG 21G6 is shown in Figure 2B (SEQ ID NO: 19), and the amino acid sequence is also shown in Figure 2B (SEQ ID NO: 20).
- the CDR1 domain of the light chain variable region corresponds to a region of SEQ ID NO: 20 (SEQ ID NO: 22), which is encoded by a region of SEQ ID NO: 19 (SEQ ID NO: 21), and the CDR2 domain of the light chain variable region corresponds to a region of SEQ ID NO: 20 (SEQ ID NO: 24), which is encoded by a region of SEQ ID NO: 19 (SEQ ID NO: 23).
- the CDR3 domain of the light chain variable region corresponds to a region of SEQ ID NO: 20 (shown as SEQ ID NO: 32), which is encoded by a region of SEQ ID NO: 19 (shown as SEQ ID NO: 31).
- nucleotide sequences can encode the amino acid sequences listed herein.
- nucleic acid compositions of the present invention while often in a native sequence (except for modified restriction sites and the like), from either cDNA, genomic or mixtures may be mutated, in accordance with standard techniques. For coding sequences, these mutations, may affect the amino acid sequence as desired.
- nucleotide sequences substantially identical to or derived from native V, D, J, constant, switches and other such sequences described herein are contemplated.
- an isolated nucleic acid can comprise an IgG 21G6 (or 21G6 IgG) heavy chain variable region nucleotide sequence as shown in Figure 2 A (SEQ ID NO: 13), or a sequence, which is at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 13.
- the nucleotides at positions 19-21 of SEQ ID NO: 13 are selected from the group consisting of TCT, TCC, TCA, TCG, CCT, CCC, CCA, CCG, AGT, and AGC.
- a nucleic acid molecule may comprise the heavy chain CDR1 nucleotide sequence of SEQ ID NO: 15, or a portion thereof.
- the nucleic acid molecule may comprise the heavy chain CDR2 nucleotide sequence of SEQ ID NO: 17, or a portion thereof. Further, the nucleic acid molecule may comprise the heavy chain CDR3 nucleotide sequence of SEQ ID NO: 29, or a portion thereof. In an exemplary embodiment, the nucleic acid molecule comprises a heavy chain CDR1 nucleotide sequence of SEQ ID NO: 15, or portion thereof, and a heavy chain CDR2 nucleotide sequence of SEQ ID NO: 17, or portion thereof, and a heavy chain CDR3 nucleotide sequence of SEQ ID NO: 29, or portion thereof.
- the nucleic acid molecules of the present invention may comprise heavy chain sequences, e.g.
- nucleic acid molecules of the present invention may comprise heavy chain sequences, which hybridize under stringent conditions, e.g. low, medium, high or very high stringency conditions, to SEQ ID NOs: 13, 15, 17, or 29.
- the invention features nucleic acid molecules having at least 80%, 90%, 95%, 96%, 97 %, 98%, and 99% sequence identity with a nucleic acid molecule encoding a heavy chain polypeptide, e.g., a heavy chain polypeptide of SEQ ID NOs: 14, 16, 18, or 30.
- the amino acid sequence at position 7 of SEQ ID NO: 14 comprises a serine or a proline.
- the invention also features nucleic acid molecules which hybridize to nucleic acid sequences encoding a heavy chain variable region of an antibody or portion thereof, e.g., a heavy chain variable region of SEQ ID NO: 14, 16, 18, or 30.
- the isolated nucleic acid encodes an IgG 21G6 (21G6 IgG) light chain variable region nucleotide sequence having a nucleotide sequence as shown in Figure 2B (SEQ ID NO: 19), or a sequence at least 80%, 90%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 19.
- the nucleic acid molecule may comprise the light chain CDR1 nucleotide sequence of SEQ ID NO: 21, or a portion thereof.
- the nucleic acid molecule may comprise the light chain CDR2 nucleotide sequence of SEQ ID NO: 23, or a portion thereof. In another embodiment, the nucleic acid molecule may comprise the light chain CDR3 nucleotide sequence of SEQ ID NO: 31, or a portion thereof. In an exemplary embodiment, the nucleic acid molecule comprises a light chain CDR1 nucleotide sequence of SEQ ID NO: 21, or portion thereof, and a light chain CDR2 nucleotide sequence of SEQ ID NO: 23, or portion thereof, and a light chain CDR3 nucleotide sequence of SEQ ID NO: 31 , or portion thereof.
- the nucleic acid molecules of the present invention may comprise light chain sequences, e.g.
- nucleic acid molecules may comprise light chain sequences, which hybridize under stringent conditions, e.g. low, medium, high or very high stringency conditions, to SEQ ID NOs: 19, 21, 23, or 31.
- Nucleic acid molecules can have at least 80%, 90%, 95%, 96%, 97 %, 98% or 99% sequence identity with a nucleic acid molecule encoding a light chain polypeptide, e.g., a light chain polypeptide of SEQ ID NOs: 20, 22, 24, or 32.
- the invention also features nucleic acid molecules which hybridize to a nucleic acid sequence encoding a light chain variable region of an antibody or portion thereof, e.g., a light chain variable region of SEQ ID NOs: 20, 22, 24, or 32.
- the invention provides an isolated nucleic acid encoding a heavy chain CDR1 domain comprising the amino acid sequence of SEQ ID NO: 16, or a fragment or modified form thereof.
- This nucleic acid can encode only the CDR1 region or can encode an entire antibody heavy chain variable region or a fragment thereof.
- the nucleic acid can encode a heavy chain variable region having a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 18.
- the invention provides an isolated nucleic acid encoding a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 30, or a fragment or modified form thereof.
- This nucleic acid can encode only the CDR2 region or can encode an entire antibody heavy chain variable region or a fragment thereof.
- the nucleic acid can encode a light chain variable region having a CDRl domain comprising the amino acid sequence of SEQ ID NO: 16.
- the invention provides an isolated nucleic acid encoding a light chain CDRl domain comprising the amino acid sequence of SEQ ID NO: 22, or a fragment or modified form thereof.
- This nucleic acid can encode only the CDRl region or can encode an entire antibody light chain variable region.
- the nucleic acid can encode a light chain variable region having a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 24.
- the isolated nucleic acid can also encode a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 32, or a fragment or modified form thereof.
- This nucleic acid can encode only the CDR2 region or can encode an entire antibody light chain variable region.
- the nucleic acid can encode a light chain variable region having a CDRl domain comprising the amino acid sequence of SEQ ID NO: 22.
- the nucleic acid encoding the heavy or light chain variable region can be of murine or human origin, or can comprise a combination of murine and human amino acid sequences.
- the nucleic acid can encode a heavy chain variable region comprising the CDRl of SEQ ID NO: 14 (SEQ ID NO: 16) and/or the CDR2 of SEQ ID NO: 14 (SEQ ID NO: 18), and/or the CDR3 of SEQ ID NO: 14 (SEQ ID NO: 30) and a human framework sequence.
- the nucleic acid can encode a light chain variable region comprising the CDRl of SEQ ID NO: 20 (SEQ ID NO: 22) and/or the CDR2 of SEQ ID NO: 20 (SEQ ID NO: 24), and/or the CDR3 of SEQ ID NO: 20 (SEQ ID NO: 32) and a human framework sequence.
- the invention further encompasses vectors containing the above-described nucleic acids and host cells containing the expression vectors.
- the invention also features polypeptides and fragments of the IgG 21G6 heavy chain variable regions and/or light chain variable regions. Any of the polypeptides encoded by nucleic acids described herein are within the scope of the invention.
- the isolated polypeptides comprise, for example, the amino acid sequences of SEQ ID NOs: 20, 22, 24, or 32, or fragments or combinations thereof; or SEQ ID NO: 14, 16, 18, or 30, or fragments or combinations thereof.
- the polypeptides of the present invention include polypeptides having at least, but not more than 20, 10, 5, 4, 3, 2, or 1 amino acid that differs from SEQ ID NOs: 20, 22, 24, 32, 14, 16, 18, or 30.
- polypeptides are polypeptides that retain biological activity, e.g., the ability to bind to the N2 self-peptide and the ability to inhibit activation of complement and/or inhibit inflammation.
- the polypeptides comprise polypeptides having at least 80%, 90%, 95%, 96%, 97%, 98%, and 99% sequence identity with a light chain variable region, or portion thereof, e.g. a light chain variable region polypeptide of SEQ ID NOs: 20, 22, 24, or 32.
- the polypeptides comprise
- polypeptides having at least 80%, 90%, 95%, 96%, 97%, 98%, and 99% sequence identity with a heavy chain variable region, or portion thereof, e.g. a heavy chain variable region polypeptide of SEQ ID NOs: 14, 16, 18, or 30.
- the invention features a polypeptide comprising the amino acid sequence of SEQ ID NO: 20 and SEQ ID NO: 14, further comprising an IRES sequence.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDR1 having the amino acid sequence of SEQ ID NO: 16. In another embodiment, antibodies that immunospecifically bind to the N2 self- peptide comprise a VH CDR2 having the amino acid sequence of SEQ ID NO: 18. In another embodiment, antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDR3 having the amino acid sequence of SEQ ID NO:30.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDR1 having the amino acid sequence of SEQ ID NO: 16 and a VH CDR2 having the amino acid sequence of SEQ ID NO: 18.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDR1 having the amino acid sequence of SEQ ID NO: 16 and a VH CDR3 having the amino acid of SEQ ID NO:30.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDR2 having the amino acid sequence of SEQ ID NO: 18 and a VH CDR3 having the amino acid of SEQ ID NO:30.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VH CDR1 having the amino acid sequence of SEQ ID NO: 16, a VH CDR2 having the amino acid sequence of SEQ ID NO: 18, and a VH CDR3 having the amino acid of SEQ ID NO:30.
- antibodies that immunospecifically bind to an N2 self-peptide comprise a VL CDR1 having the amino acid sequence of SEQ ID NO:22. In another embodiment, antibodies that immunospecifically bind to the N2 self- peptide comprise a VL CDR2 having the amino acid sequence of SEQ ID NO:24. In another embodiment, antibodies that immunospecifically bind to the N2 self-peptide comprise a VL CDR3 having the amino acid sequence of SEQ ID NO:32.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VL CDRl having the amino acid sequence of SEQ ID NO:22 and a VL CDR2 having the amino acid sequence of SEQ ID NO:24.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VL CDRl having the amino acid sequence of SEQ ID NO:22 and a VL CDR3 having the amino acid of SEQ ID NO:32.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VL CDR2 having the amino acid sequence of SEQ ID NO:24 and a VL CDR3 having the amino acid of SEQ ID NO:32.
- antibodies that immunospecifically bind to the N2 self-peptide comprise a VL CDRl having the amino acid sequence of SEQ ID NO:22, a VL CDR2 having the amino acid sequence of SEQ ID NO:24, and a VL CDR3 having the amino acid of SEQ ID NO:32.
- an antibody of the invention comprises a VH CDRl having the amino acid sequence of SEQ ID NO: 16 and a VL CDRl having the amino acid sequence of SEQ ID NO:22.
- an antibody of the present invention comprises a VH CDRl having the amino acid sequence of SEQ ID NO: 16 and a VL CDR2 having the amino acid sequence of SEQ ID NO:24.
- an antibody of the present invention comprises a VH CDRl having the amino acid sequence of SEQ ID NO: 16 and a VL CDR3 having the amino acid sequence of SEQ ID NO:32.
- an antibody of the present invention comprises a VH CDR2 having the amino acid sequence of SEQ ID NO: 18 and a VL CDRl having the amino acid sequence of SEQ ID NO:22. In another embodiment, an antibody of the present invention comprises a VH CDR2 having the amino acid sequence of SEQ ID NO: 18 and a VL CDR2 having the amino acid sequence of SEQ ID NO:24. In another embodiment, an antibody of the present invention comprises a VH CDR2 having the amino acid sequence of SEQ ID NO: 18 and a VL CDR3 having the amino acid sequence of SEQ ID NO:32.
- an antibody of the present invention comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:30, and a VL CDRl having the amino acid sequence of SEQ ID NO:22.
- an antibody of the present invention comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:30 and a VL CDR2 having the amino acid sequence of SEQ ID NO:24.
- an antibody of the present invention comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:30 and a VL CDR3 having the amino acid sequence of SEQ ID NO:32.
- anti-N2 anti-inflammatory antibodies having the properties described herein may be produced. Methods of producing antibodies are well known in the art and may be used for producing modified anti-N2 anti-inflammatory antibodies.
- the V region domains of heavy and light chains can be expressed on the same polypeptide, joined by a flexible linker to form a single-chain Fv fragment, and the scFV gene subsequently cloned into the desired expression vector or phage genome.
- a flexible linker As generally described in McCafferty et al, Nature (1990) 348:552-554, complete V H and V L domains of an antibody, joined by a flexible (Gly 4 -Ser) 3 (SEQ ID NO: 35) linker can be used to produce a single chain antibody which can render the display package separable based on antigen affinity. Isolated scFV antibodies immunoreactive with the antigen can subsequently be formulated into a pharmaceutical preparation for use in the subject method.
- An antibody of the present invention can be one in which the variable region, or a portion thereof, e.g., the complementarity determining regions (CDR or CDRs), are generated in a non-human organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and humanized antibodies are within the invention. Antibodies generated in a non-human organism, e.g., a rat or mouse, and then modified, e.g., in the variable framework or constant region, to decrease antigenicity in a human are within the invention. Any modification is within the scope of the invention so long as the antibody has at least one antigen binding portion.
- CDR or CDRs complementarity determining regions
- Chimeric antibodies e.g. mouse-human monoclonal antibodies
- Chimeric antibodies can be produced by recombinant DNA techniques known in the art. For example, a gene encoding the Fc constant region of a murine (or other species) monoclonal antibody molecule is digested with restriction enzymes to remove the region encoding the murine Fc, and the equivalent portion of a gene encoding a human Fc constant region is substituted, (see Robinson et al, International Patent Publication PCT/US86/02269; Akira, et al., European Patent
- a chimeric antibody can be further humanized by replacing sequences of the Fv variable region which are not directly involved in antigen binding with equivalent sequences from human Fv variable regions.
- General methods for generating humanized antibodies are provided by Morrison, S. L., 1985, Science 229:1202-1207 by Oi et al, 1986, BioTechniques 4:214, and by Queen et al. US 5,585,089, US 5,693,761 and US 5,693,762, the contents of all of which are hereby incorporated by reference. Those methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of immunoglobulin Fv variable regions from at least one of a heavy or light chain.
- Sources of such nucleic acid are well known to those skilled in the art and, for example, may be obtained from 7E3, an anti-GPII b III a antibody producing hybridoma.
- the recombinant DNA encoding the chimeric antibody can then be cloned into an appropriate expression vector.
- Suitable humanized antibodies can alternatively be produced by CDR substitution.
- Humanized or CDR-grafted antibodies can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDRs of an immunoglobulin chain can be replaced. See e.g., U.S. Patent 5,225,539; Jones et al. 1986 Nature 321 :552-525; Verhoeyan et al. 1988 Science 239: 1534; Beidler et al. 1988 J. Immunol. 141 :4053-4060; Winter US
- a humanized or CDR-grafted antibody will have at least one or two but generally all recipient CDRs (of heavy and/or light immunoglobulin chains) replaced with a donor CDR.
- the donor will be a rodent antibody, e.g., a rat or mouse antibody, and the recipient will be a human framework or a human consensus framework.
- the immunoglobulin providing the CDRs is called the "donor” and the immunoglobulin providing the framework is called the "acceptor.”
- the donor immunoglobulin is a non-human (e.g., rodent).
- the acceptor framework can be a naturally- occurring (e.g., a human) framework or a consensus framework, or a sequence about 85% or higher, preferably 90%, 95%, 99% or higher identical thereto.
- All of the CDRs of a particular antibody may be replaced with at least a portion of a non-human CDR or only some of the CDRs may be replaced with non-human CDRs. It is only necessary to replace the number of CDRs required for binding of the humanized antibody to the Fc receptor.
- chimeric and humanized antibodies in which specific amino acids have been substituted, deleted or added.
- preferred humanized antibodies have amino acid substitutions in the framework region, such as to improve binding to the antigen.
- a humanized antibody will have framework residues identical to the donor framework residue or to another amino acid other than the recipient framework residue.
- amino acids located in the human framework region can be replaced with the amino acids located at the corresponding positions in the mouse antibody.
- Another example of a humanized antibody is a murine monoclonal antibody having a murine variable region but modified to have a human Fc region. Such substitutions are known to improve binding of humanized antibodies to the antigen in some instances.
- amino acid substitutions, deletions or additions may be made to the antibodies described herein to inhibit or block inflammation.
- asparagine at position 297 of the IgG constant region may be substituted by alanine (N297A) to reduce glycosylation and thereby ability to activate complement and bind Fc receptor.
- N297A alanine
- Antibody fragments of the invention can be obtained using conventional procedures known to one of skill in the art. For example, digestion of an antibody with pepsin yields F(ab')2 fragments and multiple small fragments. Mercaptoethanol reduction of an antibody yields individual heavy and light chains. Digestion of an antibody with papain yields individual Fab fragments and the Fc fragment.
- the invention also features a method of making an anti-inflammatory antibody.
- the method includes: altering the sequence of an antibody, e.g., by substitution or deletion of one or more residues of a non-conserved region, a domain or residue disclosed herein, and testing the altered polypeptide for binding to N2 and inhibiting activation of complement.
- the modified antibody may comprise at least the CDRl region of SEQ ID NO: 8 (SEQ ID NO: 10), or antigen binding portions thereof, and/or at least the CDR2 region of SEQ ID NO: 8 (SEQ ID NO: 12), or antigen binding portions thereof.
- the modified antibody may comprise at least the CDRl region of SEQ ID NO: 2 (SEQ ID NO: 4), or antigen binding portions thereof, and/or at least the CDR2 region of SEQ ID NO: 2 (SEQ ID NO: 6), or antigen binding portions thereof.
- the modified antibody comprises the CDRl region of SEQ ID NO: 8 (SEQ ID NO: 10) and the CDR2 region of SEQ ID NO: 8 (SEQ ID NO: 12) or antigen binding portions thereof.
- the modified antibody comprises the CDRl region of SEQ ID NO: 2 (SEQ ID NO: 4) and the CDR2 region of SEQ ID NO: 2 (SEQ ID NO: 6) or antigen binding portions thereof.
- the modified antibody may also comprise the CDRl region of SEQ ID NO: 8 (SEQ ID NO: 10) and the CDR2 region of SEQ ID NO: 8 (SEQ ID NO: 12) and the modified antibody comprises the CDRl region of SEQ ID NO: 2 (SEQ ID NO: 4) and the CDR2 region of SEQ ID NO: 2 (SEQ ID NO: 6) or antigen binding portions thereof.
- the modified antibody may comprise at least the CDRl region of SEQ ID NO: 20 (SEQ ID NO: 22), or antigen binding portions thereof, and/or at least the CDR2 region of SEQ ID NO: 20 (SEQ ID NO: 24), or antigen binding portions thereof.
- the modified antibody may comprise at least the CDRl region of SEQ ID NO: 14 (SEQ ID NO: 16), or antigen binding portions thereof, and/or at least the CDR2 region of SEQ ID NO: 14 (SEQ ID NO: 18), or antigen binding portions thereof.
- the modified antibody comprises the CDR1 region of SEQ ID NO: 20 (SEQ ID NO: 22) and the CDR2 region of SEQ ID NO: 20 (SEQ ID NO: 24) or antigen binding portions thereof.
- the modified antibody comprises the CDR1 region of SEQ ID NO: 14 (SEQ ID NO: 16) and the CDR2 region of SEQ ID NO: 14 (SEQ ID NO: 18) or antigen binding portions thereof.
- the modified antibody may also comprise the CDR1 region of SEQ ID NO: 20 (SEQ ID NO: 22) and the CDR2 region of SEQ ID NO: 20 (SEQ ID NO: 24) and the modified antibody comprises the CDR1 region of SEQ ID NO: 14 (SEQ ID NO: 16) and the CDR2 region of SEQ ID NO: 14 (SEQ ID NO: 18) or antigen binding portions thereof.
- the modified antibody can be a human antibody having a binding affinity to the N2 self-antigen, similar, e.g., greater than, less than, or equal to, the binding affinity of the antibody produced by the hybridoma deposited with the ATCC, having the accession number PTA-9392 or PTA-9393.
- the antibody can be a non- human antibody, e.g., a cow, goat, mouse, rat, sheep, pig, or rabbit.
- the non-human antibody is a murine antibody.
- the antibody may also be a recombinant antibody.
- the antibody is a humanized antibody.
- the modified antibody may be an IgG antibody.
- the isolated antibody possess the same antigenic specificity as the antibody produced by the hybridoma deposited with the ATCC, having accession number PTA-9392 or PTA-9393.
- the antibody possessing the same antigenic specificity as the antibody produced by the hybridoma deposited with the ATCC having accession number PTA-9392 or PTA-9393 wherein the antibody is a human antibody, humanized antibody, chimeric antibody or an antibody fragment of any of thereof.
- Antibodies may be modified, for example to increase solubility and/or facilitate purification, identification, detection, and/or structural characterization. Exemplary modifications, include, for example, addition of: glutathione S-transferase (GST), protein A, protein G, calmodulin-binding peptide, thioredoxin, maltose binding protein, HA, myc, poly-arginine, poly-His, poly-His-Asp or FLAG fusion proteins and tags.
- GST glutathione S-transferase
- protein A protein G
- calmodulin-binding peptide thioredoxin
- maltose binding protein HA
- myc poly-arginine
- poly-His poly-His-Asp or FLAG fusion proteins and tags.
- an antibody may comprise one or more heterologous fusions.
- peptides may contain multiple copies of the same fusion domain or may contain fusions to two or more different domains.
- the fusions may occur at the N-terminus of the peptide, at the C-terminus of the peptide, or at both the N- and C-terminus of the peptide. It is also within the scope of the invention to include linker sequences between a peptide of the invention and the fusion domain in order to facilitate construction of the fusion protein or to optimize protein expression or structural constraints of the fusion protein.
- the peptide may be constructed so as to contain protease cleavage sites between the fusion peptide and peptide of the invention in order to remove the tag after protein expression or thereafter.
- suitable endoproteases include, for example, Factor Xa and TEV proteases.
- fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation.
- the fusion gene may be synthesized by conventional techniques including automated DNA synthesizers.
- PCR amplification of gene fragments may be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments, which may subsequently be annealed to generate a chimeric gene sequence (see, for example, Current Protocols in Molecular Biology, eds. Ausubel et al, John Wiley & Sons: 1992).
- Antibodies may be chemically modified based on linkage to a polymer.
- the polymer is typically water soluble so that the antibody to which it is attached does not precipitate in an aqueous environment, such as a physiological environment.
- the polymer may have a single reactive group, such as an active ester for acylation or an aldehyde for alkylation, so that the degree of polymerization may be controlled.
- a preferred reactive aldehyde is polyethylene glycol propionaldehyde, which is water stable, or mono CI -CIO alkoxy or aryloxy derivatives thereof (see U.S. Pat. No. 5,252,714).
- the polymer may be branched or unbranched.
- the polymer will be pharmaceutically acceptable.
- the water soluble polymer, or mixture thereof if desired may be selected from the group consisting of, for example, polyethylene glycol (PEG), monomethoxy-polyethylene glycol, dextran, cellulose, or other carbohydrate based polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol.
- PEG polyethylene glycol
- monomethoxy-polyethylene glycol dextran
- cellulose or other carbohydrate based polymers
- poly-(N-vinyl pyrrolidone) polyethylene glycol propylene glycol homopolymers
- a polypropylene oxide/ethylene oxide co-polymer polyoxyethylated polyols (e.g., glycerol
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of an antibody lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the test compound which achieves a half- maximal inhibition of symptoms) as determined in cell culture.
- IC 50 i.e., the concentration of the test compound which achieves a half- maximal inhibition of symptoms
- levels in plasma may be measured, for example, by high performance liquid chromatography.
- a single bolus of an antibody is administered prior to, contemporaneously with, or subsequent to a tissue injury.
- a single dose injection will be a few hours, a few days or a few weeks after tissue injury.
- the present invention is based in part upon the discovery that an anti-inflammatory antibody inhibits or prevents reperfusion injury.
- a single unit dosage delivery can be immediately adjacent to the site of injury or can be, for example, to a vessel that drains or flows to the site of injury.
- An anti-inflammatory antibody is administered initially at a point in time prior to the time of damage of the target organ or tissue. This may be a useful approach in subjects who are determined to be at risk for reperfusion injury, such as those with a history of reperfusion injury or those about to undergo surgery.
- a single bolus of an anti-inflammatory antibody can be followed by subsequent administrations of an anti-inflammatory antibody as continuous infusions or additional single bolus deliveries.
- the anti-inflammatory antibody may be administer in sequential exposures over a period of hours, days, weeks, months or years.
- additional therapeutic agents can be combined with, administered prior to or subsequent to administration of an anti-inflammatory antibody.
- Other therapeutic agents that may be administered with an anti-inflammatory antibody include, but are not limited to, anti-coagulation agents and complement inhibitors.
- the subject anti-inflammatory antibodies may be provided in pharmaceutically acceptable carriers or formulated for a variety of modes of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remmington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA.
- the antibody is provided for transmucosal or transdermal delivery.
- penetrants appropriate to the barrier to be permeated are used in the formulation with the polypeptide.
- penetrants are generally known in the art, and include, for example, for transmucosal administration bile salts and fusidic acid derivatives.
- detergents may be used to facilitate permeation.
- Transmucosal administration may be through nasal sprays or using suppositories. For topical
- compositions of the invention are formulated into ointments, salves, gels, or creams as generally known in the art.
- compositions according to the invention are prepared by bringing an anti-inflammatory antibody into a form suitable for administration to a subject using carriers, excipients and additives or auxiliaries.
- carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols.
- Intravenous vehicles include fluid and nutrient replenishers.
- Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases.
- Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in
- the pharmaceutical compositions are preferably prepared and administered in dose units.
- Solid dose units are tablets, capsules and suppositories and including, for example, alginate based pH dependent release gel caps.
- administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or by several smaller dose units and also by multiple
- compositions according to the invention may be administered locally or systemically in a therapeutically effective dose. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the subject. As discussed above, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various considerations are described, e.g., in Langer, Science, 249: 1527, (1990); Gilman et al. (eds.) (1990), each of which is herein incorporated by reference.
- the invention provides a pharmaceutical composition useful for administering anantibody-binding peptide to a subject in need of such treatment.
- administering the pharmaceutical composition of the invention may be accomplished by any means known to the skilled artisan.
- a “subject” refers to a mammal, most preferably a human.
- the anti-inflammatory antibody can be administered parenterally, enterically, by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, rectally and orally.
- Pharmaceutically acceptable carrier preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of nonaqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Carriers for occlusive dressings can be used to increase skin permeability and enhance antigen absorption.
- Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form.
- Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners and elixirs containing inert diluents commonly used in the art, such as purified water.
- the disease or disorder is a gastrointestinal disorder oral formulations or suppository formulations are preferred.
- Sterile injectable solutions can be prepared by incorporating a antibody-binding peptide in the required amount (e.g., about 10 ⁇ g to about 10 mg/kg) in an appropriate solvent and then sterilizing, such as by sterile filtration. Further, powders can be prepared by standard techniques such as freeze drying or vacuum drying.
- an anti-inflammatory antibody is prepared with a biodegradable carrier for sustained release characteristics for either sustained release in the GI tract or for target organ implantation with long term active agent release characteristics to the intended site of activity.
- Biodegradable polymers include, for example, ethylene vinyl acetate, polyanhydrides, polyglycolic acids, polylactic acids, collagen,
- Liposomal formulation can also be used.
- Another means of delivering anti-inflammatory antibody is by delivering host cells that express antibody-binding peptides to a site or tissue in need of repair.
- the cells may be delivered in conjunction with various delivery vehicles, including biocompatible biodegradable or non-biodegradable sponges (e.g., collagen, or other extracellular matrix materials), cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, dextran, polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound formed into a three- dimensional structure (see, for example, U.S. Pat. No. 5,858,721 to Naughton et al, the disclosure of which is incorporated herein by reference).
- biocompatible biodegradable or non-biodegradable sponges e.g., collagen, or other extracellular matrix materials
- cotton e.g., collagen
- parenteral administration such as subcutaneous, intramuscular or intravenous injection.
- the dose of the active ingredient to be administered depends on the basis of the medical prescriptions according to age, weight and the individual response of the patient.
- the daily non-weighted dosage for the patient can be between about 2.5-5.0 mg/Kg, e.g., about 2.5-3.0 mg/Kg, about 3.0-3.5 mg/Kg, about 3.5-4.0 mg/Kg, about 4.0-4.5 mg/Kg, and about 4.5-5.0 mg/Kg.
- the pharmaceutical composition for parenteral administration can be prepared in an injectable form comprising the active principle and a suitable vehicle.
- Vehicles for the parenteral administration are well known in the art and comprise, for example, water, saline solution, Ringer solution and/or dextrose.
- the vehicle can contain small amounts of excipients in order to maintain the stability and isotonicity of the pharmaceutical preparation.
- the preparation of the cited solutions can be carried out according to the ordinary modalities.
- compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack may for example comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- Anti-inflammatory antibodies may be used for treating a number of inflammatory diseases and conditions that are triggered by binding of natural IgG antibodies.
- the anti-inflammatory antibodies may be used to treat inflammatory diseases or conditions such as reperfusion injury, ischemia injury, stroke, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, rheumatoid arthritis, celiac disease, hyper- IgG immunodeficiency, arteriosclerosis, coronary artery disease, sepsis, myocarditis, encephalitis, transplant rejection, hepatitis, thyroiditis (e.g., Hashimoto's thyroiditis, Graves disease), osteoporosis, polymyositis, dermatomyositis, Type I diabetes, gout, dermatitis, alopecia areata, systemic lupus erythematosus, lichen sclerosis, ulcerative colitis, diabetic retinopathy, pelvic inflammatory disease, periodontal
- the invention features methods of treating an inflammatory disease or condition, such as e.g., ischemia-reperfusion injury, in a subject by administering to the subject a pharmaceutical composition comprising an antiinflammatory antibody as disclosed herein.
- an inflammatory disease or condition such as e.g., ischemia-reperfusion injury
- An inflammatory condition such as reperfusion or ischemic injury may result following a naturally occurring episode, e.g., as a stroke or myocardial infarction.
- Reperfusion or ischemic injury may also occur during and/or following a surgical procedure.
- Exemplary surgical procedures that cause can cause injury include a vessel- corrective technique selected from the group consisting of angioplasty, stenting procedure, atherectomy, and bypass surgery.
- reperfusion or ischemic injury occurs in a cardiovascular tissue, such as the heart.
- diseases or conditions that are triggered by binding of natural IgG antibodies may be treated or prevented in a subject by removing from the subject or inactivating a natural or pathogenic IgG and/or B cells producing the pathogenic immunoglobulin (e.g., B-1 cells as described herein), thereby reducing the amount of the pathogenic immunoglobulin and/or B cells present in the subject.
- a natural or pathogenic IgG and/or B cells producing the pathogenic immunoglobulin e.g., B-1 cells as described herein
- the methods described herein may comprise removing from the subject or inactivating a pathogenic immunoglobulin, e.g., a pathogenic IgG as described herein, and/or B-cells producing the pathogenic IgG (e.g., B-1 cells as described herein), thereby reducing the amount of the pathogenic immunoglobulin and/or B cells present in the subject.
- a pathogenic immunoglobulin e.g., a pathogenic IgG as described herein
- B-cells producing the pathogenic IgG e.g., B-1 cells as described herein
- the removing or inactivating step is performed ex vivo.
- the pathogenic immunoglobulins or B cells can be removed by hemoperfusion.
- the B cells can be removed using a B cell-specific antibody (e.g., an anti-B-1 antibody or an anti-CD5 antibody or anti-CD 11 G/CD 18).
- the pathogenic immunoglobulin e.g., an IgG
- the pathogenic immunoglobulin can be removed by contacting blood from a subject with an immobilized antigen (e.g., an ischemia-specific antigen) or an immobilized anti-idiotypic antibody.
- the removing or inactivating step of the pathogenic immunoglobulin may be performed by administering an anti-idiotypic antibody to the subject.
- the removing or inactivating step of the B cell is performed by administering to the subject a B cell targeting moiety (e.g., an antibody or an antigen) coupled to a toxin, e.g., ricin or diphteria toxin.
- a B cell targeting moiety e.g., an antibody or an antigen
- the subject is a mammal, e.g., a rodent (e.g., a mouse) or a primate (e.g., a human).
- the subject has sustained a reperfusion or ischemic injury following a naturally occurring episode, e.g., as a stroke, and the removing step is carried out within minutes, one to five hours, five to ten hours, ten to twenty hours, one to five days, following the naturally occurring episode.
- the reperfusion or ischemic injury occurs in a cardiovascular tissue, e.g., the heart, and the reperfusion or ischemic injury is prevented and/or decreased by, removing from the subject, the pathogenic immunoglobulin, and/or the B cells, prior to, during, and/or following the surgical procedure.
- the removing step can be carried out at least one to five hours, five to ten hours, ten to twenty hours, or one, two or three days prior to the surgical procedure.
- the removing step can also be continued for appropriate time intervals during and after the surgical procedure.
- mice deficient in the complement system were resistant to ischemia-reperfusion injury.
- mice deficient in complement C3 were treated in the hindlimb model.
- the C3-/- mice were partially protected from injury based on an approximate 50% reduction in permeability index (see Weiser et al. (1996) J. Exp. Med. 1857-1864).
- complement C3 is essential for induction of full injury in this murine model.
- the serum complement system can be activated by at least three distinct pathways, classical, lectin or alternative. Knowing which pathway is involved, is important as it suggests a mechanism for injury.
- the classical pathways is activated very efficiently by IgM and IgG isotypes of immunoglobulin or by the serum recognition protein C-reactive protein.
- the lectin pathway is activated following recognition of specific carbohydrates such as mannan by mannan binding lectin (MBL) (Epstein et al, (1996) Immunol 8, 29-35).
- complement C4 is required in forming an enzyme complex with C2 that catalyzes cleavage of the central component C3.
- the alternative pathway activates spontaneously leading to conversion of C3 to its active form (C3b) and attachment to foreign-or self-tissues.
- the pathway is tightly regulated as all host cells express inhibitors of amplification of the complement pathway by inactivating, or displacing the C3 convertase (Muller-Eberhard, H.J., (1988) Ann. Rev. Biochem. 57, 321-347).
- One approach for determining the pathway involved is use of mice deficient in C4, i.e., cannot form C3 convertase via classical or lectin pathways.
- mice deficient in either C3 or C4 with wild type (WT) controls in the hindlimb model revealed that C4 was also required for induction of full injury (Weiser et al. supra). This finding was important as it suggested that antibody or MBL might be involved.
- mice deficient in immunoglobulin were resistant to ischemia-reperfusion injury.
- mice totally deficient in immunoglobulin, RAG2-/- (recombinase activating gene -2 deficient) were characterized along with the complement deficient animals in the intestinal model.
- the RAG-2-/- mice were protected to a similar level as observed in the complement deficient animals (Weiser et al. supra). Since the RAG2-/- animals are also missing mature lymphocytes, it was important to determine that the pathogenic effect was antibody dependent (Shinkai et al. (1992) Cell 68, 855-867). To confirm that injury was mediated by serum antibody, the deficient animals were reconstituted with either normal mouse sera (Weiser et al. supra) or purified IgM (Williams et al. (1999) J. Appl. Physiol 86; 938-42). In both cases, the reconstituted RAG-2-/- mice were no longer protected and injury was restored. In the latter experiments, a model of intestinal injury was used as in this model, injury is thought to be
- neoantigens are either expressed or exposed on the endothelial cell surface. Circulating IgMs appear to recognize the new determinant, bind and activate classical pathway of complement. While the nature of the antigen is not known, IgM rather than IgG seems to be primarily responsible for activation of complement as reconstitution of deficient mice with pooled IgG did not significantly restore injury in the mice.
- B-1 cells have a distinct phenotype from more conventional B-2 cells in that they express low levels of IgD and CD23 and a major fraction express the cell surface protein CD5 (Hardy et al., (1994) Immunol. Rev.: 137, 91; Kantor et al. (1993) Annu. Rev. Immunol. 11, 501-538, 1993.
- B-1 cells are also distinguished by reduced circulation in mice, limited frequency in the peripheral lymph nodes and spleen and are primarily localized within the peritoneal cavity.
- mice in the intestinal I/R model were characterized. Surprisingly, the Cr2-/- mice were equally protected as the complete-antibody deficient mice. Comparison of survival over a five-day period following treatment in the intestinal model demonstrated a significant increase in mortality of the WT compared to Cr2-deficient animals. Consistent with an increased mortality, a dramatic reduction in injury was observed in tissue sections harvested from treated WT or Cr2-/- deficient mice.
- This Example describes the generation of a specific hybridoma clone from normal B-l cells and the identification of one clone that produces a pathogenic IgM.
- the pathogenic IgM was shown to restore injury in vivo to antibody deficient mice.
- B-l cells are responsible for secreting the pathogenic
- IgM IgM
- engraftment of the receptor deficient mice (Cr2-/-) with B-l cells from normal mice restored injury, confirming the importance of B-I cells.
- a panel of hybridoma clones were constructed from an enriched pool of peritoneal B-1 cells harvested from normal mice.
- the general approach for preparing hybridomas from enriched fraction of peritoneal cells includes harvesting peritoneal cells from mice treated 7 days earlier with IL-10 and subsequently enriched for CD23 negative B cells by negative selection with magnetic beads. Enriched B cells are analyzed by FACS following staining with IgM, Mac-1 and CD23 specific Mab.
- the enriched population is further activated by culturing with LPS for 24 hours. Activated cells are hybridized with fusion partner myeloma cells in the presence of PEG and grown in HAT-selective medium. Hybridomas are screened for IgM secreting clones by ELISA , and positive wells are expanded for purification of IgM.
- Treatment of antibody-deficient mice with the pooled IgM restored injury similar to that seen with pooled IgM from serum. This finding confirmed that the pathogenic IgM was among the twenty-two hybridomas produced.
- the pathogenic antibody was found to fractionate with the pool that included clone # 22.
- B-1 cells develop in early fetal life as a distinct population (Kantor et al. (1993) supra).
- B-1 cells develop from the same progenitors as conventional B cells but depending on their environment, i.e., encounter with antigen, they develop into B-1 or retain the B-2 cell phenotype (Wortis, H.H. (1992) Int. Rev. Immunol. 8, 235; Clarke, J. (1998) Exp. Med. 187, 1325-1334).
- B-1 cells are not replenished from adult bone marrow at the same frequency as B-2 cells and that their phenotype is more similar to that of early fetal liver B cells or neonatal bone marrow (BM) cells. Consistent with an early origin, their repertoire tends to be biased towards expression of more proximal V H genes and N-nucleotide addition is limited (Gu et al. (1990) EMBO J 9, 2133; Feeney, J. (1990) Exp. Med. 172, 1377).
- B-1 cells are self-renewed and that antigen stimulation might be important in their renewal, expansion or even initial selection (Hayakawa et al., (1986) Eur. J. Immunol. 16, 1313). Indeed inherent to the conventional model, B-1 cells must be antigen selected.
- BCR B-cell receptor
- B-1 cells likewise utilize co-receptor signaling to enhance the BCR signal.
- bacteria express typical B-1 cell antigens such as phosphoryl choline and it is not unreasonable that coating of bacteria with complement ligand C3d would enhance crosslinking of the co-receptor with the BCR and enhance overall signaling.
- antigens expressed at lower concentrations might require complement enhancement in order for the cognate B-cell to recognize it and expand or be positively selected.
- Another role for complement receptors is in localizing antigen on follicular dendritic cells (FDC) within the lymphoid compartment.
- FDC follicular dendritic cells
- B-l cells occupy the peritoneal tissues it is not clear if they would encounter FDC within lymphoid structures.
- the actual site or sites in which B-l cells undergo positive selection are not known. It is possible that they must encounter cognate antigen in early fetal development or in neonatal BM. If this is the case, it might be expected that complement receptors on stromal cells within these compartments bind antigen for presentation to B cells. It is possible that complement receptors could participate in both stages of development. First, they might enhance antigens signaling in initial positive selection. Secondly, as selected B-l cells are replenished at peripheral sites, complement receptors might again be involved in enhancement of BCR signaling.
- a proposed role for complement and complement receptors in positive selection of peritoneal B- l lymphocytes includes the interaction of complement-ligand coated antigens (self- and non-self), resulting in co-ligation of the CD21/CD19 co-receptor and BCR on the cell surface, in turn, leading to enhanced signaling and positive selection.
- mice were immunized with the N2 peptide (Ac- LMK MDPLNDNV (SEQ ID NO: 33)) coupled to a carrier protein (KLH). This region (N2) is highly conserved and identical in mouse and man.
- Two of the hybridomas were selected for further characterization and shown to bind the N2 peptide both in vitro and in vivo.
- pretreatment of mice with 100 ugs of a Fab '2 fragment (removal of the Fc piece) of either hybridoma blocks ischemia reperfusion injury in the murine myocardial infarction model.
- 12A6 is a IgG2b isotype. Its VH most closely matches the germ line gene 3609.11.169 sequence paired with DH: DSP2/DFL16.1 and its light chain is a V kappa 8-27 with JK1. 21G6 is an IgGl isotype with its VH matching J558.35; DH:
- DSP2.6/DSP2.4/DSP2.3 and JH JH3. Its light chain is V kappa hf24 and JK4.
- Murine anti-N2 mAb inhibits inflammation following myocardial infarction.
- B6 mice were subjected to 1 h LAD occlusion followed by 24 h reperfusion. Prior to occlusion (15 min), either saline or 150 ⁇ g of anti-N2 F(ab') 2 antibody (21G6) was injected i.v. into the mice. Following reperfusion, both serum troponin-I levels (A) and mouse IgM deposition (B) were analyzed and statistical significance for each was evaluated by
- N2 peptide and anti-N2 mAb block human IgM-mediated injury.
- Figure 4 shows (A) RAG-1-/- mice were subjected to 1 h LAD occlusion followed by 24 h reperfusion. Prior to occlusion (15 min), 400 ⁇ g of pooled individual hlgM from 10 donors was injected i.v. into the mice with either saline or 200 ⁇ g of N2 peptide. Myocardial sections were stained with Evans blue and TTC. Myocardial infarct size is expressed as a percentage infarct of the area at risk (AAR) of the left ventricle.
- AAR area at risk
- RAG-1-/- mice were treated as in (A) and analyzed for hlgM deposition (B) or serum troponin-I levels (C).
- B and C RAG-1-/- mice were subjected to 1 h LAD occlusion and 24 h reperfusion. Prior to occlusion (15 min), 400 ⁇ g hlgM was injected i.v. into the mice with either saline or 150 ⁇ g of anti-N2 F(ab') 2 antibody (21G6) and myocardial sections were analyzed as in (A).
- E RAG-1-/- mice were treated as in (D) and analyzed for hlgM deposition. In all panels, statistical significance was evaluated by Student's t test.
- Example 8 12A6 hybridoma antibody binds to the N2 self-peptide in vivo
- B6 mice were injected i.v. with fluorescently- labeled anti-N2 antibody (12A6) and anti-CD31 antibody prior to 60 min LAD occlusion and 30 min reperfusion. Following treatment, hearts were collected, fixed, and analyzed by confocal microscopy. The area at risk (left ventricle) was compared with the non-risk area (right ventricle). Quantification of the individual antibody staining as well as the merged images both in the area at risk and non-risk area is shown in Figure 5.
- any polynucleotide and polypeptide sequence which reference an accession number correlating to an entry in a public database, such as those maintained by The Institute for Genomic Research (TIGR) on the world wide web with the extension tigr.org and or the National Center for
- NCBI Biotechnology Information
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2783563A CA2783563A1 (en) | 2009-12-07 | 2010-12-07 | Anti-inflammatory antibodies and uses therefor |
AU2010328359A AU2010328359B2 (en) | 2009-12-07 | 2010-12-07 | Anti-inflammatory antibodies and uses therefor |
EP10836519.8A EP2510000B1 (en) | 2009-12-07 | 2010-12-07 | Anti-inflammatory antibodies and uses therefor |
JP2012542241A JP6018917B2 (en) | 2009-12-07 | 2010-12-07 | Anti-inflammatory antibodies and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27572309P | 2009-12-07 | 2009-12-07 | |
US61/275,723 | 2009-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011071883A1 true WO2011071883A1 (en) | 2011-06-16 |
Family
ID=44145879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/059234 WO2011071883A1 (en) | 2009-12-07 | 2010-12-07 | Anti-inflammatory antibodies and uses therefor |
Country Status (6)
Country | Link |
---|---|
US (3) | US8324352B2 (en) |
EP (1) | EP2510000B1 (en) |
JP (1) | JP6018917B2 (en) |
AU (1) | AU2010328359B2 (en) |
CA (1) | CA2783563A1 (en) |
WO (1) | WO2011071883A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014165115A1 (en) * | 2013-03-12 | 2014-10-09 | Decimmune Therapeutics, Inc. | Humanized anti-n2 antibodies |
US20150284453A1 (en) * | 2012-10-01 | 2015-10-08 | Declmmune Therapeutics, Inc. | Method of protecting cardiac function |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2783563A1 (en) * | 2009-12-07 | 2011-06-16 | Decimmune Therapeutics, Inc. | Anti-inflammatory antibodies and uses therefor |
JP7359390B2 (en) * | 2018-02-09 | 2023-10-11 | 国立大学法人大阪大学 | Antibodies or antigen-binding fragments thereof against chikungunya virus and their uses |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
EP0173494A2 (en) | 1984-08-27 | 1986-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by DNA splicing and expression |
WO1986001533A1 (en) | 1984-09-03 | 1986-03-13 | Celltech Limited | Production of chimeric antibodies |
GB2188638A (en) | 1986-03-27 | 1987-10-07 | Gregory Paul Winter | Chimeric antibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5585089A (en) | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5858721A (en) | 1986-04-18 | 1999-01-12 | Advanced Tissue Sciences, Inc. | Three-dimensional cell and tissue culture system |
US5928893A (en) * | 1995-04-08 | 1999-07-27 | Lg Chemical Ltd. | Monoclonal antibody specific for human 4-1BB and cell line producing same |
US20030099656A1 (en) * | 2001-01-26 | 2003-05-29 | Patti Joseph M. | Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections |
US20030202975A1 (en) * | 2002-02-21 | 2003-10-30 | Tedder Thomas F. | Reagents and treatment methods for autoimmune diseases |
US20040214272A1 (en) * | 1999-05-06 | 2004-10-28 | La Rosa Thomas J | Nucleic acid molecules and other molecules associated with plants |
US20050276811A1 (en) * | 2004-03-01 | 2005-12-15 | Carroll Michael C | Natural IgM antibodies and inhibitors thereof |
US20080262203A1 (en) * | 2007-04-17 | 2008-10-23 | Stephanie Jane Clegg | Novel compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
US20040131607A1 (en) | 2001-06-08 | 2004-07-08 | Carroll Michael C. | Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury |
US20100136684A1 (en) | 2004-03-01 | 2010-06-03 | Carroll Michael C | Natural IgM Antibodies |
ES2527521T3 (en) * | 2008-03-17 | 2015-01-26 | Livtech Inc. | Anti-human antibodies against Dlk-1 that have antitumor activity |
CA2783563A1 (en) * | 2009-12-07 | 2011-06-16 | Decimmune Therapeutics, Inc. | Anti-inflammatory antibodies and uses therefor |
AU2014248636B2 (en) | 2013-03-12 | 2017-03-30 | Decimmune Therapeutics, Inc. | Humanized anti-N2 antibodies |
-
2010
- 2010-12-07 CA CA2783563A patent/CA2783563A1/en not_active Abandoned
- 2010-12-07 EP EP10836519.8A patent/EP2510000B1/en not_active Not-in-force
- 2010-12-07 US US12/962,101 patent/US8324352B2/en not_active Expired - Fee Related
- 2010-12-07 AU AU2010328359A patent/AU2010328359B2/en not_active Ceased
- 2010-12-07 JP JP2012542241A patent/JP6018917B2/en not_active Expired - Fee Related
- 2010-12-07 WO PCT/US2010/059234 patent/WO2011071883A1/en active Application Filing
-
2012
- 2012-11-05 US US13/668,515 patent/US9067983B2/en not_active Expired - Fee Related
-
2015
- 2015-05-29 US US14/726,016 patent/US20160083459A1/en not_active Abandoned
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0173494A2 (en) | 1984-08-27 | 1986-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by DNA splicing and expression |
WO1986001533A1 (en) | 1984-09-03 | 1986-03-13 | Celltech Limited | Production of chimeric antibodies |
GB2188638A (en) | 1986-03-27 | 1987-10-07 | Gregory Paul Winter | Chimeric antibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5858721A (en) | 1986-04-18 | 1999-01-12 | Advanced Tissue Sciences, Inc. | Three-dimensional cell and tissue culture system |
US5693762A (en) | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5693761A (en) | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Polynucleotides encoding improved humanized immunoglobulins |
US5585089A (en) | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5928893A (en) * | 1995-04-08 | 1999-07-27 | Lg Chemical Ltd. | Monoclonal antibody specific for human 4-1BB and cell line producing same |
US20040214272A1 (en) * | 1999-05-06 | 2004-10-28 | La Rosa Thomas J | Nucleic acid molecules and other molecules associated with plants |
US20030099656A1 (en) * | 2001-01-26 | 2003-05-29 | Patti Joseph M. | Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections |
US20030202975A1 (en) * | 2002-02-21 | 2003-10-30 | Tedder Thomas F. | Reagents and treatment methods for autoimmune diseases |
US20050276811A1 (en) * | 2004-03-01 | 2005-12-15 | Carroll Michael C | Natural IgM antibodies and inhibitors thereof |
US7442783B2 (en) | 2004-03-01 | 2008-10-28 | The Cbr Institute For Biomedical Research, Inc. | Natural IgM antibodies and inhibitors thereof |
US20080262203A1 (en) * | 2007-04-17 | 2008-10-23 | Stephanie Jane Clegg | Novel compounds |
Non-Patent Citations (15)
Title |
---|
BEIDLER ET AL., J IMMUNOL., vol. 141, 1988, pages 4053 - 4060 |
BEIDLER ET AL., J. IMMUNOL., vol. 141, 1988, pages 4053 - 4060 |
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043 |
JONES ET AL., NATURE, vol. 321, 1986, pages 552 - 525 |
LIU ET AL., J. IMMUNOL, vol. 139, 1987, pages 3521 - 3526 |
LIU ET AL., PNAS, vol. 84, 1987, pages 3439 - 3443 |
MORRISON, S. L., SCIENCE, vol. 229, 1985, pages 1202 - 1207 |
NISHIMURA ET AL., CANE. RES., vol. 47, 1987, pages 999 - 1005 |
OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214 |
See also references of EP2510000A4 * |
SHAW ET AL., J. NATL. CANCER INST., vol. 80, 1988, pages 1553 - 1559 |
SUN ET AL., PNAS, vol. 84, 1987, pages 214 - 218 |
VERHOEYAN ET AL., SCIENCE, vol. 239, 1988, pages 1534 |
WOOD ET AL., NATURE, vol. 314, 1985, pages 446 - 449 |
ZHANG ET AL., PROC. NATL. ACAD. SCI., vol. 101, no. 11, 2004, pages 3886 - 3891 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150284453A1 (en) * | 2012-10-01 | 2015-10-08 | Declmmune Therapeutics, Inc. | Method of protecting cardiac function |
WO2014165115A1 (en) * | 2013-03-12 | 2014-10-09 | Decimmune Therapeutics, Inc. | Humanized anti-n2 antibodies |
US9243059B2 (en) | 2013-03-12 | 2016-01-26 | Decimmune Therapeutics, Inc. | Humanized anti-N2 antibodies and methods of treating ischemia-reperfusion injury |
JP2016512539A (en) * | 2013-03-12 | 2016-04-28 | デシミューン セラピューティクス,インコーポレイテッド | Humanized anti-N2 antibody |
US9409977B2 (en) | 2013-03-12 | 2016-08-09 | Decimmune Therapeutics, Inc. | Humanized, anti-N2 antibodies |
Also Published As
Publication number | Publication date |
---|---|
EP2510000B1 (en) | 2017-07-19 |
US20120093835A1 (en) | 2012-04-19 |
AU2010328359B2 (en) | 2015-02-05 |
EP2510000A1 (en) | 2012-10-17 |
EP2510000A4 (en) | 2013-07-24 |
AU2010328359A1 (en) | 2012-06-21 |
US9067983B2 (en) | 2015-06-30 |
US20160083459A1 (en) | 2016-03-24 |
JP2013512679A (en) | 2013-04-18 |
JP6018917B2 (en) | 2016-11-02 |
US8324352B2 (en) | 2012-12-04 |
CA2783563A1 (en) | 2011-06-16 |
US20140056871A1 (en) | 2014-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12006364B2 (en) | Anti-CD100 antibodies and methods for using the same | |
JP7143452B2 (en) | ANTIBODY THAT CAN BLOCK THE INTERACTION BETWEEN CD47 AND SIRPa, AND ITS APPLICATION | |
US20240124584A1 (en) | Igm fc and j-chain mutations that affect igm serum half-life | |
JP2021087432A (en) | Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor | |
HU230768B1 (en) | Humanized antibodies that sequester amyloid beta peptide | |
JP6363623B2 (en) | Method for increasing the level of immunoglobulin A | |
JP6370349B2 (en) | Anti-P-selectin antibodies and methods for their use and identification | |
US9409977B2 (en) | Humanized, anti-N2 antibodies | |
US20160083459A1 (en) | Anti-Inflammatory Antibodies and Uses Therefor | |
US20100136684A1 (en) | Natural IgM Antibodies | |
AU2015202351A1 (en) | Anti-inflammatory antibodies and uses therefor | |
WO2023216981A1 (en) | Fusion protein of relaxin or analogue and medical use thereof | |
CA3214739A1 (en) | Dpep-1 binding agents and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10836519 Country of ref document: EP Kind code of ref document: A1 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10836519 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010328359 Country of ref document: AU Ref document number: 2012542241 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2783563 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010328359 Country of ref document: AU Date of ref document: 20101207 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2010836519 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010836519 Country of ref document: EP |